Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Biotechnology

UFOVAX

Ji Li

Jiang Zhu

The executive team at UFOVAX has a history of experience in the fields of molecular targeting technology, pharmaceuticals, and healthcare. They have held positions at various companies, including Uvax Bio and Wilmington PharmaTech Company LLC. In addition, they have also received education from prestigious universities, such as Princeton University.

CEO and Executive Team

About

Team members

Other teams at UFOVAX

Board of Directors

Founding Team